- Home
- TLSI vs ADCT Comparison
TLSI vs ADCT Comparison
Compare TLSI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- ADCT
- Stock Information
- Founded
- TLSI 2010
- ADCT 2011
- Country
- TLSI United States
- ADCT Switzerland
- Employees
- TLSI N/A
- ADCT N/A
- Industry
- TLSI Medical Specialities
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- ADCT Health Care
- Exchange
- TLSI Nasdaq
- ADCT Nasdaq
- Market Cap
- TLSI 160.4M
- ADCT 143.1M
- IPO Year
- TLSI N/A
- ADCT 2020
- Fundamental
- Price
- TLSI $5.62
- ADCT $1.49
- Analyst Decision
- TLSI Strong Buy
- ADCT Strong Buy
- Analyst Count
- TLSI 6
- ADCT 5
- Target Price
- TLSI $11.75
- ADCT $8.50
- AVG Volume (30 Days)
- TLSI 66.8K
- ADCT 344.2K
- Earning Date
- TLSI 03-27-2025
- ADCT 03-27-2025
- Dividend Yield
- TLSI N/A
- ADCT N/A
- EPS Growth
- TLSI N/A
- ADCT N/A
- EPS
- TLSI N/A
- ADCT N/A
- Revenue
- TLSI $29,431,000.00
- ADCT $70,837,000.00
- Revenue This Year
- TLSI $55.43
- ADCT $6.81
- Revenue Next Year
- TLSI $50.09
- ADCT $11.24
- P/E Ratio
- TLSI N/A
- ADCT N/A
- Revenue Growth
- TLSI 58.99
- ADCT 1.84
- 52 Week Low
- TLSI $3.50
- ADCT $1.39
- 52 Week High
- TLSI $10.42
- ADCT $5.38
- Technical
- Relative Strength Index (RSI)
- TLSI 55.78
- ADCT 39.46
- Support Level
- TLSI $5.06
- ADCT $1.41
- Resistance Level
- TLSI $5.72
- ADCT $1.68
- Average True Range (ATR)
- TLSI 0.37
- ADCT 0.12
- MACD
- TLSI 0.03
- ADCT -0.03
- Stochastic Oscillator
- TLSI 90.65
- ADCT 16.00
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.